# US 2004/0019924 A1 · Nuclear transfer embryo formation method

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0019924 A1
- Document ID: US20040019924A1
- Status: Published application
- Kind: A1
- Application number: 10/208,653
- Filed: 2002-07-29
- Published: 2004-01-29
- Earliest claimed: 2002-07-29
- Assignees: Trustees of Tufts College
- Inventors: Eric W. Overstrom; Daniela Fischer
- Web page: https://patentgrep.com/patent/US20040019924A1

## CPC

- C12N 15/8771: {Bovine embryos}
- C12N 15/873: Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
- A01K 2227/101: Bovine
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

A nuclear transfer embryo is formed by destabilizing microtubules of an oocyte, whereby essentially all endogenous chromatin collects at a second polar body during meiosis of an oocyte. The oocyte is fused with the nucleus of a donor somatic cell of the same species of said oocyte prior to cessation of extrusion of the second polar body from the oocyte, thereby forming the nuclear transfer embryo. In one embodiment, the nuclear transfer embryo is employed to impregnate an animal, such as a mammal. In another embodiment, the donor nucleus is transgenic.

## Claims

### Claim 1

A method of forming a nuclear transfer embryo, comprising the steps of:
a) destabilizing microtubules of an oocyte, whereby essentially all endogenous chromatin collects at a second polar body during meiosis of said oocyte; and
b) combining the oocyte with at least the nucleus of a donor cell of the same species of said oocyte prior to cessation of extrusion of the second polar body from said oocyte, thereby forming a nuclear transfer embryo.

### Claim 2 (depends on 1)

The method of claim 1, wherein the microtubules are destabilized by combining the oocytes with a chemical selected from the group consisting of demecolcine, paclitaxel, phalloidin, colchicine, and nocodozole.

### Claim 3 (depends on 2)

The method of claim 2, further includes activating the oocyte prior to exposing the oocyte to said chemical.

### Claim 4 (depends on 1)

The method of claim 1, where the microtubules are destabilized by exposing the microtubules to electromagnetic radiation.

### Claim 5 (depends on 4)

The method of claim 4, where the electromagnetic radiation is selected from the group consisting of x-rays and heat.

### Claim 6 (depends on 1)

The method of claim 1, wherein the microtubules are destabilized by exposure of the oocyte to a change in pH or osmolality.

### Claim 7 (depends on 1)

The method of claim 1, wherein the activated oocyte is in a telophase II or anaphase II stage of meiosis.

### Claim 8 (depends on 1)

The method of claim 1, wherein the oocyte is in a metaphase II stage of meiosis.

### Claim 9 (depends on 8)

The method of claim 8, further including the step of activating the oocyte.

### Claim 10 (depends on 1)

The method of claim 1, wherein the donor cell is an activated donor cell.

### Claim 11 (depends on 10)

The method of claim 10, wherein the activated donor cell is in the G1 stage of a mitotic cell cycle.

### Claim 12 (depends on 11)

The method of claim 11, wherein the somatic activated donor cell is a fibroblast activated donor cell.

### Claim 13 (depends on 12)

The method of claim 12, wherein the somatic activated donor cell is an epithelial activated donor cell.

### Claim 14 (depends on 1)

The method of claim 1, wherein the donor cell is a somatic cell.

### Claim 15 (depends on 14)

The method of claim 14, wherein the donor cell is an adult somatic cell.

### Claim 16 (depends on 14)

The method of claim 14, wherein the donor cell is an embryonic somatic cell.

### Claim 17 (depends on 1)

The method of claim 1, wherein the oocyte is mammalian.

### Claim 18 (depends on 17)

The method of claim 17, wherein the mammal is non-human.

### Claim 19 (depends on 18)

The method of claim 18, wherein the oocyte and the donor cell are of the same species.

### Claim 20 (depends on 1)

The method of claim 1, wherein the donor cell is transgenic.

### Claim 21

A method of cloning a mammal, comprising:
a) destabilizing microtubules of an oocyte, whereby essentially all endogenous genetic material collects at a second polar body during meiosis of said oocyte; and
b) combining the oocyte with at least the nucleus of a donor cell of the same species of said oocyte prior to cessation of extrusion of the second polar body from said oocyte, thereby forming a nuclear transfer embryo.
c) impregnating a mammal of the same species as the nuclear transfer embryo with the nuclear transfer embryo under conditions suitable for gestation of the cloned mammal; and
d) gestating the embryo, thereby causing the embryo to develop into the cloned mammal.

### Claim 22 (depends on 10)

The method of claim 10, wherein the compound that destabilizes the microtubules is selected from the group consisting of demecolcine, nocodazole, colchicine, phalloidin and paclitaxel.

### Claim 23

A method of producing a transgenic mammal, comprising the steps of:
a) destabilizing microtubules of an oocyte, whereby essentially all endogenous genetic material collects at a second polar body during meiosis of said oocyte; and
b) combining the oocyte with at least the nucleus of a donor cell of the same species of said oocyte prior to cessation of extrusion of the second polar body for said oocyte, thereby forming a nuclear transfer embryo.
c) impregnating a mammal of the same species as the nuclear transfer embryo with the nuclear transfer embryo under conditions suitable for gestation of the transgenic mammal; and
d) gestating the embryo, thereby causing the embryo to develop into the transgenic mammal.

### Claim 24

A method of cloning a mammalian fetus, comprising the steps of:
a) destabilizing microtubules of an oocyte, whereby essentially all endogenous genetic material collects at a second polar body during meiosis of said oocyte; and
b) combining the oocyte with at least the nucleus of a donor somatic cell of the same species of said oocyte prior to cessation of extrusion of the second polar body from said oocyte, thereby forming a nuclear transfer embryo.
c) impregnating a mammal of the same species as the nuclear transfer embryo with the nuclear transfer embryo under conditions suitable for gestation of the cloned mammalian fetus; and
d) gestating the embryo, thereby causing the embryo to develop into the cloned mammalian fetus.

### Claim 25

A method of forming a non-human, mammalian nuclear transfer embryo, comprising the steps of:
a) destabilizing microtubules of an oocyte, whereby essentially all endogenous genetic material collects at a second polar body during meiosis of said oocyte; and
b) combining the oocyte with at least the nucleus of a donor somatic cell of the same species of said oocyte prior to cessation of extrusion of the second polar body from said oocyte, thereby forming a nuclear transfer embryo.

### Claim 26

A method of cloning a non-human mammal, comprising the steps of:
a) destabilizing microtubules of an oocyte, whereby essentially all endogenous genetic material collects at a second polar body during meiosis of said oocyte; and
b) combining the oocyte with at least the nucleus of a donor somatic cell of the same species of said oocyte prior to cessation of extrusion of the second polar body from said oocyte, thereby forming a nuclear transfer embryo;
c) impregnating a non-human mammal of the same species as the nuclear transfer embryo with the nuclear transfer embryo under conditions suitable for gestation of the cloned non-human mammal; and
d) gestating the embryo, thereby causing the embryo to develop into the cloned non-human mammal.

### Claim 27

A method of producing a transgenic non-human mammal, comprising the steps of:
a) destabilizing microtubules of an oocyte, whereby essentially all endogenous genetic material collects at a second polar body during meiosis of said oocyte; and
b) combining the oocyte with at least the nucleus of a donor somatic cell of the same species of said oocyte prior to cessation of extrusion of the second polar body from said oocyte, thereby forming a nuclear transfer embryo.
c) impregnating a non-human mammal of the same species as the nuclear transfer embryo with the nuclear transfer embryo under conditions suitable for gestation of the transgenic mammal; and
d) gestating the embryo, thereby causing the embryo to develop into the transgenic non-human mammal.

### Claim 28

A method of cloning a non-human mammalian fetus, comprising the steps of:
a) destabilizing microtubules of an oocyte, whereby essentially all endogenous genetic material collects at a second polar body during meiosis of said oocyte; and
b) combining the oocyte with at least the nucleus of a donor somatic cell of the same species of said oocyte prior to cessation of extrusion of the second polar body from said oocyte, thereby forming a nuclear transfer embryo.
c) impregnating a non-human mammal of the same species as the nuclear transfer embryo with the nuclear transfer embryo under conditions suitable for gestation of the cloned mammalian fetus; and
d) gestating the embryo, thereby causing the embryo to develop into the cloned non-human mammalian fetus.

### Claim 29

A method of producing a protein of interest in an animal, comprising the steps of:
a) destabilizing microtubules of an oocyte, whereby essentially all endogenous genetic material collects at a second polar body during meiosis of said oocyte; and
b) combining the oocyte with at least the nucleus of a donor cell of the same species of said oocyte prior to cessation of extrusion of the second polar body from said oocyte, thereby forming a nuclear transfer embryo.
c) impregnating a mammal of the same species as the nuclear transfer embryo with the nuclear transfer embryo under conditions suitable for gestation of the cloned mammal;
d) gestating the embryo, thereby causing the embryo to develop into the cloned mammal; and
e) purifying the protein of interest from the cloned animal.

### Claim 30 (depends on 29)

The method of claim 29, wherein purification of the protein of interest is expressed in tissue, cells or a bodily secretion of the cloned animal.

### Claim 31 (depends on 29)

The method of claim 29, wherein the tissue, cells or bodily secretion is selected from the group consisting of: milk, blood, urine, hair, mammary gland, muscle, viscera.

### Claim 32 (depends on 31)

The method of claim 31, wherein said viscera is selected from the group consisting of: brain, heart, lung, kidney, pancreas, gall bladder, liver, stomach, eye, colon, small intestine, bladder, uterus and testes.

### Claim 33

A method of producing a heterologous protein in a transgenic animal comprising the steps of:
a) destabilizing microtubules of an oocyte, whereby essentially all endogenous genetic material collects at a second polar body during meiosis of said oocyte; and
b) combining the oocyte with at least the nucleus of a donor cell of the same species of said oocyte prior to cessation of extrusion of the second polar body from said oocyte, thereby forming a nuclear transfer embryo.
c) impregnating a mammal of the same species as the nuclear transfer embryo with the nuclear transfer embryo under conditions suitable for gestation of a transgenic cloned mammal;
d) gestating the embryo, thereby causing the embryo to develop into the transgenic cloned mammal; and
e) purifying the protein of interest from the transgenic cloned animal.

### Claim 34 (depends on 33)

The method of claim 33, wherein the genetically engineered nucleus includes an operatively linked promoter.

### Claim 35 (depends on 34)

The method of claim 34, wherein said promoter is selected from the group consisting of: a host endogenous promoter, an exogenous promoter and a tissue-specific promoter.

### Claim 36 (depends on 35)

The method of claim 35, wherein said tissue-specific promoter is selected from the group consisting of: mammary-specific promoter, blood-specific promoter, muscle-specific promoter, neural-specific promoter, skin-specific promoter, hair-specific promoter and urinary-specific promoter.

### Claim 37

A method of forming a nuclear transfer embryo, comprising the steps in the following order:
a) combining an oocyte with at least the nucleus of a donor cell of the same species of said oocyte;
b) activating the oocyte; and
c) destabilizing microtubules of the oocyte, whereby essentially all endogenous chromatin collects at a second polar body during meiosis of said oocyte, thereby forming a nuclear transfer embryo.

### Claim 38 (depends on 37)

The method of claim 37, wherein the oocyte is in a metaphase II stage of meiosis prior to activation.

### Claim 39 (depends on 38)

The method of claim 38, wherein the oocyte is in a telophase II or anaphase II stage of meiosis after activation.

### Claim 40

A method of forming a nuclear transfer embryo, comprising the steps of:
a) activating an oocyte;
b) combining the activated oocyte with at least the nucleus of a donor cell of the same species of said oocyte in less than about 45 minutes after activation of the oocyte; and
c) destabilizing microtubules of the activated oocyte, whereby essentially all endogenous chromatin collects at a second polar body during meiosis of said oocyte, thereby forming a nuclear transfer embryo.
